NEW YORK (GenomeWeb News) – Response Genetics announced today contracts with Blue Cross and Blue Shield of Minnesota and Blue Cross and Blue Shield of Nebraska.
The Los Angeles-based molecular diagnostic company is now in-network with eight Blue Cross Blue Shield plans. Today's announcement follows agreements inked between Response Genetics and four payors last month.
The company offers genomic testing focused on lung, colon, and gastric cancer, as well as melanoma. The tests are used by physicians to help guide them in choosing therapeutic treatments for their patients.
Last week, Response Genetics launched a public offering of about 4.5 million shares of its common stock anticipated to raise $4.8 million in net proceeds.